Get the Stockscreener App
1.3199
5.04%
-0.0701
Inflarx N V stock is traded at $1.3199, with a volume of 191.83K.
It is down -5.04% in the last 24 hours and down -45.23% over the past month.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
See More
Previous Close:
$1.39
Open:
$1.37
24h Volume:
191.83K
Relative Volume:
0.52
Market Cap:
$93.32M
Revenue:
-
Net Income/Loss:
$-46.12M
P/E Ratio:
-1.5273
EPS:
-0.8642
Net Cash Flow:
$-41.02M
1W Performance:
-17.50%
1M Performance:
-45.23%
6M Performance:
-18.01%
1Y Performance:
-24.57%
1-Day Range:
$1.31
$1.4399
1-Week Range:
$1.31
$1.64
52-Week Range:
$1.165
$2.815
Inflarx N V Stock (IFRX) Company Profile
Compare IFRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
1.32 | 93.32M | 0 | -46.12M | -41.02M | -0.8642 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.80 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
690.68 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
636.58 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.52 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
113.32 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-05-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-28-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-06-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-08-20 | Initiated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Apr-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-05-19 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-05-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-05-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Jun-05-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-05-19 | Downgrade | SunTrust | Buy → Hold |
| Jan-29-19 | Initiated | Robert W. Baird | Outperform |
| Dec-10-18 | Initiated | Credit Suisse | Outperform |
| Jul-13-18 | Initiated | BMO Capital Markets | Outperform |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-28-18 | Initiated | SunTrust | Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Inflarx N V Stock (IFRX) Latest News
InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting - GlobeNewswire
Can InflaRx's Vilobelimab Transform Treatment for These Rare Skin Diseases? - StockTitan
InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences - GlobeNewswire
InflaRx N.V. to Release Fourth Quarter 2024 Financial Results and Participate in Key Investor Conferences - Nasdaq
InflaRx Financial Results Coming March 20: What's Next for this Anti-Inflammatory Therapeutics Developer? - StockTitan
Short Interest in InflaRx (NASDAQ:IFRX) Decreases By 13.7% - MarketBeat
InflaRx Concludes $30 Million Public Offering - TipRanks
InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewswire
InflaRx commences offering of ordinary shares and pre-funded warrants - MSN
InflaRx launches public offering of shares and warrants - MSN
What is IFRX’s price-to-sales ratio telling us about the company’s value? - US Post News
InflaRx dips 16%, prices $30M stock offering - MSN
Sector Update: Health Care Stocks Flat to Higher Premarket Friday -February 14, 2025 at 09:19 am EST - Marketscreener.com
InflaRx Slumps Premarket After Pricing $30 Million Offering of Ordinary Shares, Pre-Funded Warrants - Marketscreener.com
InflaRx Secures Critical $30M Funding: Pipeline Expansion for Vilobelimab in Focus - StockTitan
InflaRx N.V. Announces Pricing of $16.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - Nasdaq
InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewswire
Form 424B5 InflaRx N.V. - StreetInsider.com
InflaRx announces ordinary shares and warrants offering, no amount given - TipRanks
InflaRx launches public offering of shares and warrants By Investing.com - Investing.com South Africa
InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewswire
InflaRx Unveils Strategic Funding Round: Pipeline Expansion for Vilobelimab Trials - StockTitan
InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update - br.ADVFN.com
Short Interest in InflaRx (NASDAQ:IFRX) Expands By 15.0% - MarketBeat
Adlai Nortye And 2 Other Penny Stocks On US Exchanges To Watch - Simply Wall St
InflaRx (NASDAQ:IFRX) Sees Significant Growth in Short Interest - Defense World
InflaRx (IFRX) Stock Sees After-Market Gains - Stocks Telegraph
InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference - GlobeNewswire
InflaRx to Present at Guggenheim SMID Cap Biotech Conference: Spotlight on Vilobelimab Pipeline - StockTitan
Short Interest in InflaRx (NASDAQ:IFRX) Rises By 15.0% - MarketBeat
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug - MSN
InflaRx (NASDAQ:IFRX) Earns Buy Rating from HC Wainwright - Defense World
InflaRx stock reiterated at Buy at H.C. Wainwright after EU drug approval - MSN
InflaRx secures European Commission approval for ARDS drug - European Biotechnology News
InflaRx (NASDAQ:IFRX) Given Buy Rating at HC Wainwright - MarketBeat
InflaRx wins EU approval for Gohibic in Covid-19-induced ARDS - Yahoo Finance
InflaRx Secures EU Approval for GOHIBIC in Treating COVID-19-Induced ARDS - TipRanks
InflaRx Receives European Commission Approval for GOHIBIC® - GlobeNewswire
InflaRx gets EU okay for Gohibic for COVID-19 respiratory distress - Seeking Alpha
InflaRx's GOHIBIC Makes History as First EU-Approved Treatment for COVID-19 ARDS - StockTitan
Inflarx N V Stock (IFRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.72%
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):